- Home
- BIYA vs KPRX Comparison
BIYA vs KPRX Comparison
Compare BIYA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIYA
- KPRX
- Stock Information
- Founded
- BIYA 2017
- KPRX 1998
- Country
- BIYA China
- KPRX United States
- Employees
- BIYA N/A
- KPRX N/A
- Industry
- BIYA
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BIYA
- KPRX Health Care
- Exchange
- BIYA NYSE
- KPRX Nasdaq
- Market Cap
- BIYA 7.8M
- KPRX 9.1M
- IPO Year
- BIYA 2025
- KPRX N/A
- Fundamental
- Price
- BIYA $0.75
- KPRX $2.86
- Analyst Decision
- BIYA
- KPRX Strong Buy
- Analyst Count
- BIYA 0
- KPRX 1
- Target Price
- BIYA N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BIYA 3.1M
- KPRX 1.4M
- Earning Date
- BIYA 05-13-2025
- KPRX 08-08-2025
- Dividend Yield
- BIYA N/A
- KPRX N/A
- EPS Growth
- BIYA N/A
- KPRX N/A
- EPS
- BIYA N/A
- KPRX N/A
- Revenue
- BIYA $12,809,211.00
- KPRX $20,000.00
- Revenue This Year
- BIYA N/A
- KPRX N/A
- Revenue Next Year
- BIYA N/A
- KPRX N/A
- P/E Ratio
- BIYA N/A
- KPRX N/A
- Revenue Growth
- BIYA 10.66
- KPRX N/A
- 52 Week Low
- BIYA $0.59
- KPRX $2.51
- 52 Week High
- BIYA $8.00
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- BIYA N/A
- KPRX 42.65
- Support Level
- BIYA N/A
- KPRX $2.68
- Resistance Level
- BIYA N/A
- KPRX $3.22
- Average True Range (ATR)
- BIYA 0.00
- KPRX 0.18
- MACD
- BIYA 0.00
- KPRX -0.03
- Stochastic Oscillator
- BIYA 0.00
- KPRX 33.21
About BIYA BAIYA INTERNATIONAL GROUP INC
Baiya International Group Inc is a company which operates through its subsidiary Gongwuyuan operates a cloud-based internet platform to provide one-stop crowdsourcing recruitment and SaaS-enabled HR solutions in the flexible employment marketplace. The Company's business is focused around on four primary services which are job matching services, entrusted recruitment services, project outsourcing services and abor dispatching services in the flexible employment market within China, mainly in the core manufacturing regions including the Pearl River Delta and Yangtze River Delta region.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.